PhRMA’s submission (7 February 2014, USTR-2013-0040) to USTR’s 2014 Special 301 Review requests USTR classify India as a Priority Foreign Country citing the fact that India “continues to embrace these damaging policies, especially its IP rules, by publicly highlighting them… Continue Reading
The National Association of Manufacturers’s (NAM) submission (7 February 2014, USTR-2013-0040) to USTR’s 2014 Special 301 Review requests that USTR designate India as a Priority Foreign Country citing concerns with India’s actions in multilateral fora including the UNFCCC, WTO and… Continue Reading
The Biotechnology Industry Organization (BIO) submission (7 February 2014, USTR-2013-0040) to USTR’s 2014 Special 301 Review requested USTR to designate India a Priority Foreign Country. BIO expressed concerns over the robust use of patent oppositions in India: The Indian generic… Continue Reading
PhRMA
Link to submissions here.
Canada
Canadian judiciary has created a heightened standard for patentable utility.
Boseley, Sarah. 17 January 2014. “South African pharma firms accused of planning to delay patents law reform.” The Guardian. http://www.theguardian.com/world/2014/jan/17/south-african-pharma-accused-delay-patents-law-reform
De Wet, Phillip. 17 January 2014. “Motsoaledi: Big pharma’s ‘satanic’ plot is genocide.” Mail & Guardian. http://mg.co.za/article/2014-01-16-motsoaledi-big-pharmas-satanic-plot-is-genocide/
From AstraZeneca’s 20-F, section on Risk Factors, for fiscal year ended December 31, 2012. Number of words in Item 1A: 8621 Compulsory licensing of patents: 45 3D. Risk Factors The information (including tabular data) set forth or referenced under the… Continue Reading
From Amgen’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.
Item 1A. RISK FACTORS
From Eli Lilly’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 1A: 2168
Compulsory licensing of patents: 0
Item 1A. Risk Factors
From Johnson & Johnson’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 1A: 1314
Compulsory licensing of patents: 0
Item 1A.RISK FACTORS